Products for Research Use Only
RegisterLogin

CCT244747

CAT: 0804-HY-18175-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18175-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM.
CAS Number
1404095-34-6
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
Checkpoint Kinase (Chk)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CCT244747.html
Purity
99.46
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
N#CC1=NC=C(NC2=NC=C(C3=CN(C)N=C3)C(OC)=C2)N=C1O[C@H](C)CN(C)C
Molecular Formula
C20H24N8O2
Molecular Weight
408.46
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Lainchbury M, et al. Discovery of 3-alkoxyamino-5- (pyridin-2-ylamino) pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55 (22) :10229-40.|[2]Walton MI, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012 Oct 15;18 (20) :5650-61.|[3]Patel R, et al. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Radiother Oncol. 2017 Mar;122 (3) :470-475.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Chk1

Related Products

CatalogName
HY-18958-01CCT245737
HY-18958A(S) -CCT245737

Alternative Products

CatalogName
B5880-50CCT244747
A15550-25CCT244747 25mg
A15550-50CCT244747 50mg
A15550-10CCT244747 10mg
A15550-5CCT244747 5mg
A15550-2CCT244747 2mg

Popular Products